3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Breast Neoplasms
47
Neoplasm Metastasis
9
Neoplasms
8
Prostatic Neoplasms
7
Brain Neoplasms
7
Endometrial Neoplasms
6
Glioblastoma
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Meningioma
3
Carcinoma, Renal Cell
3
Sarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Oligodendroglioma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Liposarcoma
2
Hematologic Neoplasms
2
Glioma
2
Breast Neoplasms, Male
2
Breast Diseases
2
Breast Cancer Female
2
Venous Thromboembolism
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Interventions
Cyclophosphamide
53
Etoposide
33
Temozolomide
28
Irinotecan
28
Melphalan
25
Filgrastim
25
Topotecan
24
Carboplatin
24
3-Iodobenzylguanidine
23
Isotretinoin
20
Granulocyte Colony-Stimulating Factor
17
sargramostim
16
humanized 3F8 anti-GD2 monoclonal antibody
16
dinutuximab
16
Granulocyte-Macrophage Colony-Stimulating Factor
16
fludarabine
15
Vincristine
15
Doxorubicin
15
Cisplatin
15
Peripheral Blood Stem Cell Transplantation
14
Interleukin-2
14
Busulfan
13
naxitamab
12
Thiotepa
12
Radiotherapy
12
aldesleukin
11
fludarabine phosphate
10
etoposide phosphate
8
Mesna
8
Ifosfamide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroblastoma
×
abemaciclib
×
Clear all
NCT02644460
2023-10-26
AflacST1501
Emory University
Phase 1
Completed
53 enrolled